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Background: The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-
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of time-to-event (TTE) end points is rarely precise and lacks uniformity across trials. End point deﬁnition can impact trial
results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Deﬁnition for the
Assessment of Time-to-event End points in CANcer trials) aims to provide recommendations for deﬁnitions of TTE end
points. We report guidelines for RCT in sarcomas and gastrointestinal stromal tumors (GIST).
Methods:We ﬁrst carried out a literature review to identify TTE end points (primary or secondary) reported in publica-
tions of RCT. An international multidisciplinary panel of experts proposed recommendations for the deﬁnitions of these
end points. Recommendations were developed through a validated consensus method formalizing the degree of
agreement among experts.
Results: Recommended guidelines for the deﬁnition of TTE end points commonly used in RCT for sarcomas and
GIST are provided for adjuvant and metastatic settings, including DFS, TTF, time to progression and others.
Conclusion: Use of standardized deﬁnitions should facilitate comparison of trials’ results, and improve the quality of trial
design and reporting. These guidelines could be of particular interest to research scientists involved in the design, conduct,
reporting or assessment of RCT such as investigators, statisticians, reviewers, editors or regulatory authorities.
Key words: guidelines, randomized controlled trial, time-to-event end point, efﬁcacy measure, sarcoma, gastrointestinal
stromal tumors
introduction
In randomized clinical trial (RCT) in cancer, the validated and
most objectively deﬁned evaluation criterion is overall survival
(OS), deﬁned as the time interval between randomization and
death (all causes). Therapeutic progress, which in certain con-
texts has signiﬁcantly reduced mortality, the development of
new types of cytostatic drugs as well as the multiplication of
lines of treatment have resulted in the need for end points that
measure efﬁcacy with precision and that are available earlier
than OS. Such alternative composite time-to-event (TTE) end
points include for example progression-free survival (PFS) in
second-line treatment. These potential surrogate end points are
increasingly being used to replace OS [1] and their development
is strongly inﬂuenced by the goal to reduce the number of patients
in clinical trials, the duration and ultimately the cost of RCT.
As recommended by the International Conference on
Harmonisation (ICH) guidelines [2] and the CONSORT state-
ment [3], each TTE end point should be precisely deﬁned. This
implies specifying the date of origin, the list of events to be con-
sidered as failures and the censoring process. In addition, we
expect that, for a given disease and setting, each TTE end point
should encompass the same set of events across trials. However,
most TTE end points are often poorly deﬁned, and when a def-
inition is provided, it can vary between publications, as under-
lined by recent works [4, 5] and by the Food and Drug
Administration [6]. For illustration, Mathoulin-Pélissier et al.
showed that a precise deﬁnition of TTE end points was reported
for only 52% of cancer RCT published in major journals [4].
Toulmonde et al. showed that clear deﬁnitions of primary and
secondary outcome measures were reported in only 33% of pub-
lished RCT reporting on the treatment of sarcomas [5]. Similar
results have been highlighted for phase II sarcoma trials [7].
The heterogeneity of TTE end point deﬁnitions has been
highlighted by the international community, as demonstrated
by recent publications recommending the deﬁnition of speciﬁc
criteria and/or the preferred use of certain criteria in speciﬁc
localizations such as for colorectal cancer [8], hepatocellular car-
cinoma [9], breast cancer [10] or lymphoma [11]. Most of these
recommendations were based on experts’ opinions, without a
formal international consensus process, which could explain
why some have not yet been widely adopted in practice. To our
knowledge, no deﬁnition of TTE end points has yet been proposed
for sarcomas and gastrointestinal stromal tumors (GIST). This
lack of standardized deﬁnitions clearly constitutes a limitation to
the use of alternative TTE end points as efﬁcacy end points.
It is important to distinguish between the process of selecting
the relevant end point and the process of deﬁning this end
point. The selection of TTE end points to assess a therapeutic
strategy will depend on the characteristics of the trial including
settings (adjuvant versus metastatic) and treatments (systemic,
local or any combination thereof). As such, the choice of the
primary end point will be trial-speciﬁc. On the other hand, once
the end point is identiﬁed, it has to be appropriately deﬁned,
ideally using a standardized deﬁnition to ensure future compari-
sons.
Based on a formal consensus process, we developed the inter-
national DATECAN initiative (Deﬁnition for the Assessment of
Time-to-event Endpoints in CANcer trials) [12], which aims to
obtain standardized consensus deﬁnitions for multiple cancer
sites: sarcomas/GIST, pancreas, breast, stomach/esophagus,
head and neck, colon/rectum, kidney/bladder and lung cancers.
Here, we report guidelines for the deﬁnitions of TTE end points
used in cancer RCT in sarcoma and GIST treatment.
methods
The DATECAN project was initially launched in 2010 for three
cancer sites: sarcoma/GIST, pancreatic and breast cancers. The
coordinating committee (CC) for sarcoma and GIST included
three experts (CB, SMP, MO). In addition to the CC members,
the steering committee included sarcoma/GIST experts in
medical oncology (NP, PC), radiation oncology (OSN, MD) and
surgery (SB). An independent group of experts, the rating com-
mittee (RC), was in charge of scoring the questionnaires.
consensus process
A formal consensus method was used to develop these guide-
lines [13, 14]. We relied on a modiﬁed Delphi consensus
method and limited ourselves to two rounds of questionnaires
with a ﬁnal in-person meeting to discuss items for which
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consensus has not been reached after two rounds of rating. The
purpose of the formal consensus method is to formalize the
degree of agreement among experts, using iterative ratings with
feedback to identify and select points on which there is
disagreement or uncertainty. The guidelines are subsequently
based on agreement scores. The formal consensus method
involves the following steps (Figure 1): (i) assessment of the evi-
dence with regard to the research question; (ii) elaboration and
pretesting of the questionnaire to collect experts’ opinions;
(iii) scoring of the questionnaires; (iv) analysis of the experts’ opi-
nions and drafting of the ﬁnal report; (V) peer review phase; (vi)
diffusion of the recommendations. An overview of these steps is
provided in supplementary Data S1, available at Annals of
Oncology online. We refer the reader to an earlier publication for a
full description of the methodology of the consensus process [12].
literature reviews
We conducted literature reviews (i) to assess whether guidelines
had been previously developed for TTE end points used in trials
for the treatment of sarcomas and GIST and (ii) to list TTE end
points commonly reported, either as primary or secondary end
points. The used research algorithms are available in supple-
mentary Data S2, available at Annals of Oncology online.
questionnaires
In the ﬁrst round, all experts of the RC received the same ques-
tionnaire (one for sarcoma, one for GIST) to score each TTE end
point on a scale of 1 (totally disagree) to 9 (totally agree), accord-
ing to whether various clinical events should be regarded as
events in the deﬁnition of TTE outcomes. In the second round,
each expert of the RC received a personalized questionnaire
(supplementary Data S3, available at Annals of Oncology online).
Items for which strong consensus had been reached after the ﬁrst
round were highlighted. For items without consensus, the distri-
butions of scores obtained at the ﬁrst round were summarized
(minimum, maximum and median scores), and the initial score
of the RC expert was indicated. Experts were asked to rescore
items for which consensus had not been reached. By construction,
Selection of experts for the 2
committees:
SC :Steering Committee
RC: Rating Committee  
First-round rating process
(RC – by mail)
Analysis and synthesis of the
questionnaires
(SC) 
Formal Consensus Method
(Modified Delphi method) 
Final report and diffusion
of the guidelines
(SC + RC)  
Development and diffusion of the
questionnaires (SC) 
In-person meeting lead by the SC:
Presentation of the results to the RC
Problem definition
(SC: expert sollicitation + synthesis of literature)
Figure 1. Modiﬁed Delphi method used in the DATECAN initiative to reach consensus for time-to-event end points in randomized controlled trials for
sarcomas/GIST.
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the formal consensus process aims to guide experts to position
themselves, while allowing them to maintain their opinion.
results
selection of TTE end points to be deﬁned
and clinical events of interest
We identiﬁed 14 TTE end points from the literature review and
established a list of clinical events that could be included in the
deﬁnition of these end points (Table 1).
experts for the scoring process
The CC drafted a list of 57 experts for the RC. Of the 32 experts
who ﬁlled in the ﬁrst questionnaire, 28 (87%) also participated in
the second round of rating. The 28 experts (supplementary Data
S4–S6, available at Annals of Oncology online) were specialists in
medical oncology (n = 14; 50%), radiation oncology (n = 3; 11%),
surgery (n = 7; 25%), epidemiology/biostatistics (n = 3, 11%) and
pathology (n = 1, 3%). They were from institutions in various
countries: France, Germany, Italy, Netherlands, Poland, United
States and UK. Each expert was a member of one or more co-
operative groups including ASCO (American Society of Clinical
Oncology); ASTRO (American Society for Radiation Oncology);
CTOS (Connective Tissue Oncology Society); EORTC (European
Organization for Research and Treatment of Cancer); GSF
(French Sarcoma Group); ISG (Italian Sarcoma Group); RTOG
(Radiation Therapy Oncology Group); SARC (Sarcoma Alliance
for Research through Collaboration); SFRO (French Society for
Radiation Oncology); SWOG (South-West Oncology Group) and
UK NCRI (UK National Cancer Research Institute).
consensus rates after the two rounds of rating
The consensus process involved two rounds of rating (ﬁrst
round: November 2010 to November 2011; second round
March 2012 to May 2012) and one face-to-face meeting (3 June
2012, Chicago, IL). In the sarcoma questionnaire, overall,
experts rated a total of 224 events pertaining to the 14 TTE end
points. The same number of events had to be rated for GIST,
leading to a total of 448 events. The scoring process is summar-
ized in Supplementary Data S1 (available at Annals of Oncology
online). After the ﬁrst round, strong consensus was reached for
37 (8%) of the events. After the second round, strong consensus
was reached for 306 events (68%), and strong or relative consen-
sus was reached for 327 events (73%).
face-to-face meeting
After the rating process, strong consensus was not reached for
142 events covering all 14 end points for sarcomas and GIST.
Discussion was therefore needed for these events and took place
during the face-to-face meeting. Before discussing each event on
an individual basis, and with the aim of harmonization, experts
present at the meeting ﬁrst made a number of decisions. The
aim of this preliminary discussion was fourfold: to select the
items that would be discussed, to maintain the consensus
process even though not all experts attended the meeting and
were therefore unavailable for discussion, to decide on the pro-
cedure to adopt in case of absence of consensus and to attempt
to adopt homogeneous rules for sarcomas and for GIST. A
summary of these preliminary decisions is available online (sup-
plementary Data S7, available at Annals of Oncology online).
standardized deﬁnitions of TTE end points
Table 2 summarizes the events to be included in the deﬁnition
of each TTE end point following the consensus process with a
longer version available online (supplementary Data S8, avail-
able at Annals of Oncology online). Of the 14 end points initially
proposed, 2 were considered ambiguous and/or redundant with
other end points (failure-free survival (FFS), and relapse-free
survival, RFS). As such, experts discouraged their use. Common
deﬁnitions were adopted for sarcomas and GIST. The reference
date is usually the date of randomization, but it can also be the
date of diagnosis or treatment initiation depending on the study.
End points were deﬁned according to the setting. Two end
points were speciﬁcally deﬁned for the adjuvant setting (or
disease no longer detectable): disease-free survival (DFS) and
(distant) metastasis-free survival. For the metastatic setting, the
following end points were deﬁned: PFS, local progression-free
Table 1. Time-to-event end points considered for the elaboration of
guidelines for their definitions, and clinical events to be considered
for inclusion in definitions
Time-to-event end points
Disease-specific survival (DSS)
Disease-free survival (DFS)
Relapse-free survival (RFS)
Locoregional relapse-free survival (LRRFS)
(Distant) metastasis-free survival (DMFS)
Failure-free survival (FFS)
Progression-free survival (PFS)
Local progression-free survival (LPFS)
Metastatic progression-free survival (MPFS)
Time-to-treatment failure (TTF)
Time to progression (TTP)
Time-to-local progression (TTLP)
Time-to-locoregional progression (TTLRP)
Time-to-distant progression (TTDP)
Clinical events
Death
Death related to primary cancer/to progression
Death related to a second cancer
Death related to protocol treatment
Death related to other causes
Unknown cause of death
End of treatment
Due to toxicity related to treatment
Due to toxicity unrelated to treatment
Loss of follow-up
Relapse/recurrence/progression
Local
Regional
Metastatic
Second sarcoma cancer (or second GIST)
Second nonsarcoma cancer (or second non-GIST)
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survival and metastatic progression-free survival. Finally, deﬁni-
tions were provided for end points that can be used in any
setting: disease-speciﬁc survival, locoregional relapse-free sur-
vival, time to progression (TTP), time-to-local progression,
time-to-locoregional progression, time-to-distant progression,
time-to-treatment failure.
validation of the guidelines and peer review
Minutes of the in-person meeting which included the ﬁnal
guidelines were validated by email by all participating experts of
the RC and next submitted to a peer review group for external
review who provided a formal and advisory opinion on the
content and form of the initial version of the guidelines (supple-
mentary Data S4, available at Annals of Oncology online).
discussion
We propose guidelines for the deﬁnitions of TTE end points to
be used in RCT evaluating treatments on sarcomas and GIST.
Following the ﬁrst round of rating which included 28
Table 2. DATECAN guidelines for standardized definitions of time-to-event end points in randomized controlled trials assessing treatment of
sarcomas and GIST
Clinical events to be included in definition of the time-to-event end points
Time-to-event end
points
Death due to
primary cancer
(primary site)
Death due to
primary cancer
(meta. disease)
Death due
to second
cancer
Death due to
protocol
treatment
Death due
to other
causes
Death due to
unknown
cause
Local
events
Regional
events
Metastatic
events
All settings
Disease-specific
survival
X X X
Locoregional
relapse-free
survival
X X X X X X X X
Time to
progression
X X X X X
Time-to-local
progression
X X
Time-to-
locoregional
progression
X X X
Time-to-distant
progression
X X
Time-to-
treatment
failure
X X X X X X
Adjuvant setting
Disease-free
survival
X X X X X X X X X
(Distant)
metastasis-free
survival
X X X X X X X
Metastatic setting
Progression-free
survival
X X X X X X X X X
Local
progression-free
survival
X X X X X X X
Metastatic
progression-free
survival
X X X X X X X
NOTE 1: It was recommended NOT to include the following events in any of the time-to-event end points: end of treatment due to toxicity related to
treatment; end of treatment due to toxicity unrelated to treatment; loss to follow-up; second cancer.
NOTE 2: Relapse-free survival and failure-free survival were considered irrelevant/ambiguous end points and the use of other TTE end points is
recommended.
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international experts from various medical specialties, strong
consensus was reached for only 8% of the items and strong or
relative consensus was reached for 12%. This lack of initial con-
sensus highlighted the disparity of experts’ opinions and the
need for harmonization. These consensus rates improved to
68% (strong consensus) and 73% (strong or relative consensus)
at the second round. The primary reason for observing an im-
provement in the consensus rates is related to the design of the
consensus process. By construction, the formal consensus
process aims to guide experts to take position, while allowing
them to maintain their opinion at each scoring round. Another
reason for explaining such improvement is the different rules
used to deﬁne consensus after each round. Rules for the second
round are slightly relaxed to ensure that the systematic exclusion
of a proposal by a rater blocks the consensus process [12, 13].
Questionnaires did not make the distinction between adju-
vant and metastatic settings. Yet, this absence of distinction
between settings cannot explain entirely the divergence of opi-
nions between experts. Indeed, although the strong consensus
rate was extremely low at the ﬁrst round (8%), it went up to 68%
at the second round without adding any speciﬁcation of the
setting, suggesting that absence of speciﬁcation of the setting
was not responsible for the low consensus rate observed initially.
Discussion of the setting was introduced at the meeting which
allowed to distinguish those items to be used in one speciﬁc
setting or in both, and thus to provide more concise deﬁnitions.
For example PFS should be preferred for metastatic settings,
while DFS should be kept for adjuvant situations only.
The consensus process underlined that two end points were
not particularly relevant, either because of redundancy or ambi-
guity. Results of the second rating round suggested that the
same events should be included for RFS (deﬁned for all set-
tings), DFS (deﬁned for the adjuvant setting) and PFS (deﬁned
for the metastatic setting). To reduce ambiguity and to ensure
precision, experts proposed not to use the TTE end point RFS,
but instead rely on DFS and PFS, respectively, for the adjuvant
and metastatic settings.
FFS was also subject to debate. Speciﬁcally, following the
second round of rating, there was no consensus for the inclusion
of second cancers, and experts did not reach a consensus at the
meeting either. Other events to be included in FFS were similar
to those included in the deﬁnition of DFS and PFS. As a result,
it was judged that this TTE end point did not add any relevant
information and should not be used as an end point in RCT.
Finally, disease-speciﬁc survival (DSS) was initially named
cancer-speciﬁc survival. Since no consensus was reached
after the two scoring rounds, experts at the meeting
considered that this term was ambiguous and propose to change
it to DSS.
Our initial list of TTE end points was established following a
literature review of recent randomized trials. The review high-
lighted that a majority of RCT for sarcomas and GIST assessed
two or more TTE end points, usually OS, and either PFS, DFS
or TTP, as also discussed in recent reviews [15, 16]. Although
not all of the 12 end points deﬁned in these guidelines are used
on a frequent basis, they can be relevant (as primary or second-
ary end points) in speciﬁc trials depending on the setting and
treatment investigated. Our objective was to propose a large
panel of deﬁnitions, so that researchers can ﬁnd a standardized
deﬁnition for the outcome that best suits the objective of their
study.
The initial literature review also showed that the generic
term, event-free survival (EFS), was commonly used but could
have multiple deﬁnitions [17–23]. For illustration, in a trial of
children with osteosarcoma without clinically detectable
disease, EFS was deﬁned as the time from study entry until
adverse event or last patient contact, whichever came ﬁrst [18].
Adverse events included disease progression, diagnosis of
second malignant neoplasm, or death before disease progres-
sion. On the other hand, EFS included relapse after complete
response, death from any cause, and nonresponse (taken as
date of change to ‘off-protocol’ therapy) in a trial of nonmeta-
static rhabdomyosarcoma in children [17]. Again, this reﬂects
the need for concise and precise deﬁnitions of TTE end points.
We can also wonder if the use of alternative deﬁnitions for a
same outcome could have affected the conclusions of these
trials, since it has been shown that different deﬁnitions can
lead to different trial conclusion, as highlighted for colorectal
and breast cancer [24, 25].
We have provided some general guidance for deﬁning mul-
tiple TTE end points; nevertheless, some of them have to be
reﬁned according to the clinical setting. For example in the case
of retroperitoneal sarcoma, when we evaluate the role of peri-
operative radiotherapy based on locoregional relapse-free sur-
vival, it must be precisely deﬁned if peritoneal lymph nodes or
liver metastases are part of locoregional relapse. This example
illustrates the importance of the dialog between clinicians and
statisticians when designing clinical trials.
Similarly, several tools are available to measure progression
and/or relapse (e.g. RECIST [26] or Choi criteria [27]). It is
however important to distinguish between the ‘concept’ and the
‘measures’, that is, between, ‘which’ outcomes to measures and
‘how’ to measure them. Both are crucial when designing trials,
but complex enough so that they could not be addressed at once
in this work. Measurement tools (but also the calendar of sur-
veillance, imaging techniques etc.) must be deﬁned study by
study while accounting for the evolution of the conceptual ele-
ments to be included in the deﬁnitions of the end points. Just as
the development of standardized deﬁnitions, these issues could
be addressed with consensus processes using independently dif-
ferent trials’ scenarios (disease, setting, treatment).
We deliberately did not include recommendations about the
censoring process. When a clinical event is not included in a
deﬁnition, it can be censored, ignored or accounted for (using
competing-risk analysis) in the statistical analysis and the
selected method will be study-speciﬁc depending on objectives
(Additional discussion in supplementary Data S9, available at
Annals of Oncology online).
Using composite TTE end points requires that the speciﬁc
events be collected during patients’ follow-up. When designing
the trial, this implies clearly deﬁning the TTE end points used
as primary and secondary end points, the events that constitute
these end points, the schedule and duration of patient follow-up
as well as the tools to measure these events (e.g. RECIST [26] or
Choi criteria [27]). Since an end point is constituted by several
events, it is important that events beyond the ﬁrst one observed
be collected. For example assuming PFS is the primary end
point, local progression can preclude distant progression, but
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only the date of the local progression will be used for the estima-
tion of PFS. Patient follow-up and data collection beyond
local progression can provide complementary information with
regards to treatment effect on distant progression. Hudis et al.
provide an extensive discussion on this issue of follow-up and
data collection [10] and emphasize that patient follow-up and
data collection should go beyond the occurrence of the ﬁrst
event. Similarly, the cause of death and the site of ﬁrst metastatic
progression should be collected, including their timing. When
reporting study results, a breakdown of the type of events that
constitute each TTE end point in addition to the usual estimated
median survival time should be reported whenever possible.
Finally, formal consensus techniques are recognized methods
for developing core outcome sets to measure in clinical trials
[28]. The formal consensus methodology and the participation
of international experts should increase the validity and the
utility of these guidelines, and as such should contribute to the
generalizability and the acceptability of the resulting recommen-
dations and their wide-scale implementation in future research.
conclusion
The formal consensus process was used to elaborate standar-
dized deﬁnitions of TTE end points in RCT for sarcomas and
GIST. The availability of these guidelines should improve inter-
national comparisons of trials’ results. These recommendations
could be disseminated for acquisition and endorsement by
researchers and academic groups participating in clinical re-
search. In addition, such guidelines could be of interest to other
potential users including reviewers and editors of scientiﬁc jour-
nals which have recently shown increased interest in the quality
of reporting clinical trials [4, 5, 29], regulatory authorities [6] or
any research scientist or initiative interested in improving
outcome measurements and reporting of clinical trials [30]. We
therefore emphasize that it is particularly important to collect
and publish detailed data on those distinct clinical events that
contribute to these TTE end points, including events that follow
occurrence of a ﬁrst event.
Future perspectives of the DATECAN project and ongoing
work include extensions to additional cancer sites (breast
cancer, pancreatic cancer, stomach/esophagus, kidney, bladder,
head and neck, colon, lung cancers), assessment of the impact
of these deﬁnitions on academic cancer RCT as well as evalu-
ation of the statistical properties of the newly deﬁned intermedi-
ate end points (in particular PFS and DFS) as surrogates for OS.
This ongoing work should inform us on the performance of
these end points to adequately capture treatment effect depend-
ing on the disease, setting (adjuvant, metastatic) and treatment
(local, cytotoxic, cytostatic etc.).
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